Related Experiment Video
Updated: Jun 16, 2026
13:42
Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
Published on: March 8, 2013
Immunoadsorption in patients with dilated cardiomyopathy.
Lars R Herda1, Stephan B Felix, Alexander Staudt
1Department of Internal Medicine B, Ernst-Moritz-Arndt-University, Greifswald, Germany.
Atherosclerosis. Supplements
|February 5, 2010
Summary
Immunoadsorption (IA/IgG) therapy shows promise for dilated cardiomyopathy (DCM) patients. This treatment may improve heart function and reduce inflammation, offering a new option for heart failure management.
Area of Science:
- Cardiology
- Immunology
- Internal Medicine
Background:
- Dilated cardiomyopathy (DCM) involves ventricular enlargement and dysfunction.
- Immune system disturbances, including IgG antibodies against myocardial antigens, are common in DCM.
- These antibodies may contribute to DCM pathogenesis via inflammation and receptor activation.
Purpose of the Study:
- To evaluate the therapeutic potential of immunoadsorption (IA) with IgG substitution (IA/IgG) in DCM patients.
- To assess the impact of IA/IgG on clinical symptoms, cardiac function, and hemodynamics.
- To investigate the effect of IA/IgG on myocardial inflammation in DCM.
Main Methods:
- Clinical studies involving immunoadsorption (IA) using protein A columns.
- Administration of IgG substitution in conjunction with IA (IA/IgG).
- Assessment of patient symptoms, myocardial function, hemodynamic parameters, and myocardial inflammation.
Main Results:
- IA/IgG demonstrated positive effects on symptoms, myocardial function, and hemodynamics in DCM patients.
- A reduction in myocardial inflammation was observed in patients treated with IA/IgG.
- IA/IgG may offer benefits beyond conservative medical treatment.
Conclusions:
- Immunoadsorption with IgG substitution (IA/IgG) represents a potential new therapeutic strategy for heart failure in DCM.
- IA/IgG may help manage immune-mediated mechanisms contributing to DCM.
- Further research supports IA/IgG as an adjunct therapy for DCM.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...